Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
JACC Basic Transl Sci
.
2021 Dec 27;6(12):946-947.
doi: 10.1016/j.jacbts.2021.10.013.
eCollection 2021 Dec.
Authors
Ying X Gue
1
,
Giordano Pula
2
,
Gregory Y H Lip
1
3
4
Affiliations
1
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
2
Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Eppendorf, Hamburg, Germany.
3
Liverpool Centre for Cardiovascular Science, Liverpool John Moores University, Liverpool, United Kingdom.
4
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
PMID:
35024499
PMCID:
PMC8733743
DOI:
10.1016/j.jacbts.2021.10.013
No abstract available
Keywords:
coronavirus; crizanlizumab; endothelial; inflammation; thrombosis.
Publication types
Editorial
Comment